Now Enrolling

A Clinical Study for Adults with Atopic Keratoconjunctivitis

Verify Eligibility

What is the TRAK Study?

The Treatment of Atopic Keratoconjunctivitis, or TRAK Study, is being conducted to see if a new, investigational topical eye drop is safe and effective in treating signs and symptoms of AKC in adults.

The study is 17 weeks long with 7 scheduled visits. You will put one drop in each eye, four times per day, for 12 weeks.

Verify Eligibility
📎 Download Patient Brochure

What is Atopic Keratoconjunctivitis?

Atopic keratoconjunctivitis, or AKC, is a chronic inflammatory condition that affects the eyes and eyelids.

AKC is often linked to eczema, asthma, or other allergies. Common signs and symptoms include:

  • Itchy eyes

  • Redness or irritation

  • Watery or teary eyes

  • Sticky or stringy discharge

  • Swollen eyelids or skin around the eyes that feels dry or thick

  • Burning or stinging sensation

  • Blurry vision or trouble seeing clearly

  • Sensitivity to light

Verify Eligibility

Study Participation

You may be able to join this study if you are ages 18-65 and

  1. have AKC in both eyes;
  2. have experienced another atopic condition, such as eczema, asthma, or hay fever;
  3. and have chronic allergic blepharoconjunctivitis and/or keratoconjunctivitis
Verify Eligibility

Why Participate

  • You may have access to a new investigational treatment only available to study participants
  • Your participation in this study may help inform future approaches to managing AKC
  • Your participation may contribute valuable information that advances clinical research

Study Site Locations